Eli Lilly and Company has extended its post-earnings recovery past the $1,021 mark, but options traders are quietly adding downside protection even as short sellers pull back — a divergence worth watching heading into the August results.
The clearest shift this week is in options positioning. The put/call ratio has climbed to 1.17, running two standard deviations above its 20-day average of 1.07. That is the most defensively skewed reading in several weeks, and it arrives while the stock itself is posting gains — up 3.2% on the week and 10.2% over the past month. The pattern points to investors hedging a rally rather than anticipating a reversal, but the elevated skew is notable regardless of motive. The 52-week high on PCR is 1.37, so the current reading is elevated but not extreme; there is room for the hedge to deepen.
Short interest, by contrast, tells a less charged story — and a different one from the May 15 spike flagged in last week's note. After briefly touching 9.2 million shares on the 15th, shorts have trimmed back quickly, with the figure falling to 7.68 million by May 19, equivalent to roughly 0.86% of the free float. That is well within the range that has characterised this stock all year. Borrow costs at 0.50% are unremarkable. Availability is essentially unconstrained, with over 520 million shares available to lend — no pressure on the borrow market whatsoever. The ORTEX short score has edged down to 29.7 from 31 a week ago. Bears are not building a position here.
Analyst support remains firmly in place. Barclays lifted its target to $1,400 earlier this month — the most aggressive on the Street — while Cantor Fitzgerald and Morgan Stanley both raised targets through April and early May, all maintaining positive ratings. The consensus price target is around $1,210, implying roughly 18% upside from current levels. The lone dissenter remains HSBC, which downgraded to Reduce back in March with an $850 target — a call that now sits more than $170 below where the stock trades. Bulls anchor their case on projected 2027 EPS of around $44.75 and the scaling trajectory of tirzepatide. Bears focus on the risk that tirzepatide growth disappoints, that forglipron's launch fails to meet elevated expectations, and that pipeline acquisitions underdeliver. The stock trades at roughly 26x trailing earnings and 15x book — a premium that leaves little room for execution missteps. EPS momentum factor scores of 78 over 30 days and 76 over 90 days suggest the earnings revision cycle remains supportive for now.
On institutional flows, the picture is broadly constructive. Capital Research added over 1.3 million shares in the most recently reported period, making it the most active of the large passive and active managers among the top holders. Vanguard and BlackRock also added modestly. The Lilly Endowment, the largest single holder at just over 10% of shares, trimmed a small amount in early May — consistent with its long-running pattern of periodic sales rather than any strategic shift. Insider activity is similarly routine: a modest net sell figure of around $16.3 million over 90 days, driven largely by the Endowment and small award-related sales by CFO Lucas Montarce in February.
The next scheduled earnings release is August 5. After the April 30 print — which delivered a 13% single-day gain and a 14.5% five-day move — the bar for the next quarter is materially higher. What to watch between now and then is whether the options hedge continues to build as the stock pushes higher, and whether any further headline risk on the FDA adverse event database or the Supreme Court legal backdrop shifts the PCR toward the upper end of its 52-week range.
See the live data behind this article on ORTEX.
Open LLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
